Cavitation Technologies, Inc. Announces Definitive Agreements with BrightFlixx Finance (Luxembourg) S.A. for Aggregate Proposed Cash Consideration of $42 Million

CVAT signs $42 million all-cash buyout deal; tender offers not yet commenced.

What the company is saying

Cavitation Technologies, Inc. (OTCQB:CVAT) has executed definitive purchase agreements with BrightFlixx Finance (Luxembourg) S.A. for all-cash tender offers targeting all outstanding shares of both CVAT and Alchemy Beverages, Inc. The company highlights an aggregate proposed cash consideration of $42 million, split as $35 million for CVAT and $7 million for Alchemy. These new agreements replace previously terminated deals with European Guarantee Services S.à r.l., but retain the same financing institution, Bright Wealth Banking. The announcement emphasizes continuity in transaction participants and terms, framing this as a factor that should expedite regulatory and tender offer processes. CEO Neil Voloshin and Dr. Kassem Lahham both stress the constructive, forward-moving nature of the process and the intent to keep shareholders informed. The company is preparing a Form 8-K filing with the SEC and notes that the tender offers have not yet commenced, with required filings and formal offers still pending.

What the data suggests

The disclosed figures are clear: $42 million in total proposed cash consideration, with $35 million allocated for Cavitation Technologies and $7 million for Alchemy Beverages. The agreements are described as definitive and binding, but the transaction has not yet advanced to the tender offer stage, and no shares have changed hands. The new agreements directly replace prior ones with European Guarantee Services S.à r.l., which have been terminated, but the same financing institution, Bright Wealth Banking, remains involved. No operational, revenue, or profitability data are provided, and there is no disclosure of valuation multiples or premium to market. The process is at the signed-agreement stage, with regulatory filings and actual tender offers still to come. All forward steps—filings, commencement of offers, and closing—remain subject to regulatory and procedural execution.

Analysis

The announcement is factual and proportionate, detailing the execution of definitive purchase agreements for a $42 million all-cash tender offer, with clear identification of counterparties and financing. The language is positive but restrained, focusing on the process and next regulatory steps rather than making exaggerated claims about future benefits or synergies. While several statements are forward-looking (e.g., expected commencement of tender offers and regulatory filings), these are procedural and do not overstate the likelihood or impact of the transaction. The capital intensity is high, as the transaction involves a substantial cash outlay, but this is standard for a tender offer and is not paired with speculative or long-dated benefit claims. No operational, revenue, or profitability data are disclosed, but this is not expected in a transaction announcement of this type. There is no evidence of narrative inflation or overstatement.

Risk flags

• ●Execution risk is significant, as the transaction is contingent on the successful commencement and completion of tender offers, which have not yet begun. Delays or complications in regulatory filings or SEC review could push out the timeline or jeopardize closing.
• ●There is counterparty risk, as the transaction depends on BrightFlixx Finance (Luxembourg) S.A. and its financing partner, Bright Wealth Banking, following through with the full $42 million cash consideration. Any change in their financial position or commitment could impact the deal.
• ●Regulatory risk is present, since the transaction requires filings with the SEC and must comply with the Securities Exchange Act of 1934. Any regulatory objection or delay could materially affect the outcome.
• ●Disclosure risk exists because no information is provided on the offer price per share, premium to market, or the rationale for the $35 million and $7 million valuations. Investors lack data to assess whether the offer is attractive relative to market value or fundamentals.

Bottom line

Cavitation Technologies, Inc. has signed binding agreements for a $42 million all-cash buyout, with $35 million earmarked for CVAT shareholders and $7 million for Alchemy Beverages, but the tender offers themselves have not yet started. The continuity of transaction parties and financing suggests a stable process, but all value realization is still dependent on regulatory filings, SEC review, and the actual launch and completion of the tender offers. Investors have no visibility into the per-share offer, premium, or underlying valuation, making it difficult to judge deal attractiveness. The most important next step is the formal commencement of the tender offers and related SEC filings, which will provide actionable details. Until those filings occur, the deal remains at the agreement stage, with execution, regulatory, and counterparty risks still in play.

Announcement summary

(OTCQB: CVAT) Cavitation Technologies, Inc. announced it has entered into definitive purchase agreements with BrightFlixx Finance (Luxembourg) S.A. for cash tender offers for all outstanding shares of Cavitation Technologies, Inc. and Alchemy Beverages, Inc. The aggregate proposed cash consideration under these agreements is $42 million, with $35 million allocated for CVAT and $7 million for Alchemy, subject to the terms and conditions of the definitive purchase agreements. These new agreements with BrightFlixx Finance (Luxembourg) S.A. replace prior tender offer agreements with European Guarantee Services S.à r.l. (EGS), which have now been terminated. The material terms of the new agreements are substantially similar to those previously contemplated, and financing is provided by Bright Wealth Banking, the same institution involved in the prior transaction. Cavitation Technologies, Inc. will file a Current Report on Form 8-K with the Securities and Exchange Commission (SEC) in connection with the execution of these agreements. BrightFlixx Finance (Luxembourg) S.A. expects to commence the applicable tender offers and make the required filings in accordance with the Securities Exchange Act of 1934 and SEC regulations. Neil Voloshin, Chief Executive Officer of CVAT, stated that the execution of these definitive tender offer agreements reflects continuity in the transaction process, with the same core participants and financing institution involved, which is intended to expedite the regulatory and tender-offer process. Dr. Kassem Lahham commented that BrightFlixx Finance (Luxembourg) S.A. is moving forward with the new definitive agreements and looks forward to working constructively with the companies and their advisers to advance the proposed all-cash tender offers in accordance with the definitive purchase agreements and applicable regulatory requirements. The tender offers described in the release have not yet commenced. Upon commencement, BrightFlixx Finance (Luxembourg) S.A. expects to file Tender Offer Statements on Schedule TO, including an offer to purchase, a letter of transmittal, and related documents, with the SEC. Investors and security holders are urged to read the tender offer statements and any future filings regarding the proposed transactions, as they will contain important information and may be updated or amended from time to time.

Disagree with this article?